FABP1 Protein Human

<strong>Human FABP1 Protein</strong>_x000D_ <strong>Catalog number:</strong> B2010540_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 19 kDa_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular tool for various studies_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> FABPL, Z-protein, Fatty acid-binding protein 1 liver, L-FABP, FABP1, FABP-1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Schroeder F, McIntosh AL, Martin GG, Huang H, Landrock D, Chung S, Landrock_x000D_ KK, Dangott LJ, Li S, Kaczocha M, Murphy EJ, Atshaves BP, Kier AB. Fatty Acid_x000D_ Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the_x000D_ Endocannabinoid System and Dyslipidemias. Lipids. 2016 Jun;51(6):655-76._x000D_ _x000D_ 2: Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome._x000D_ Nat Rev Dis Primers. 2018 Sep 13;4(1):23._x000D_ _x000D_ 3: Griffin BR, Faubel S, Edelstein CL. Biomarkers of Drug-Induced Kidney_x000D_ Toxicity. Ther Drug Monit. 2019 Apr;41(2):213-226._x000D_ _x000D_ 4: Guzmán C, Benet M, Pisonero-Vaquero S, Moya M, García-Mediavilla MV,_x000D_ Martínez-Chantar ML, González-Gallego J, Castell JV, Sánchez-Campos S, Jover R._x000D_ The human liver fatty acid binding protein (FABP_1) gene is activated by FOXA1_x000D_ and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in_x000D_ nonalcoholic fatty liver disease. Biochim Biophys Acta. 2013 Apr;1831(4):803-18._x000D_ _x000D_ 5: Huang H, McIntosh AL, Landrock KK, Landrock D, Storey SM, Martin GG, Gupta S,_x000D_ Atshaves BP, Kier AB, Schroeder F. Human FABP1 T94A variant enhances cholesterol_x000D_ uptake. Biochim Biophys Acta. 2015 Jul;1851(7):946-55._x000D_ PMC4408243._x000D_ _x000D_ 6: Martin GG, Huang H, McIntosh AL, Kier AB, Schroeder F. Endocannabinoid_x000D_ Interaction with Human FABP1: Impact of the T94A Variant. Biochemistry. 2017 Sep_x000D_ 26;56(38):5147-5159._x000D_ _x000D_ 7: Huang H, McIntosh AL, Martin GG, Landrock D, Chung S, Landrock KK, Dangott_x000D_ LJ, Li S, Kier AB, Schroeder F. FABP1: A Novel Hepatic Endocannabinoid and_x000D_ Cannabinoid Binding Protein. Biochemistry. 2016 Sep 20;55(37):5243-55._x000D_ _x000D_ 8: Rodriguez Sawicki L, Bottasso Arias NM, Scaglia N, Falomir Lockhart LJ,_x000D_ Franchini GR, Storch J, Córsico B. FABP1 knockdown in human enterocytes impairs_x000D_ proliferation and alters lipid metabolism. Biochim Biophys Acta Mol Cell Biol_x000D_ Lipids. 2017 Dec;1862(12):1587-1594._x000D_ _x000D_ 9: McIntosh AL, Huang H, Storey SM, Landrock KK, Landrock D, Petrescu AD, Gupta_x000D_ S, Atshaves BP, Kier AB, Schroeder F. Human FABP1 T94A variant impacts fatty_x000D_ acid metabolism and PPAR-α activation in cultured human female hepatocytes. Am J_x000D_ Physiol Gastrointest Liver Physiol. 2014 Jul 15;307(2):G164-76._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32038102/">10: Lu YC, Chang CC, Wang CP, Hung WC, Tsai IT, Tang WH, Wu CC, Wei CT, Chung_x000D_ FM, Lee YJ, Hsu CC. Circulating fatty acid-binding protein 1 (FABP1) and_x000D_ nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Int_x000D_ J Med Sci. 2020 Jan 14;17(2):182-190. </a>_x000D_ _x000D_ <strong>Products Related to Human FABP1 Protein</strong><a href="https://moleculardepot.com/product-category/Proteins/">: Proteins</a>